Berenberg Bank Reiterates Judges Scientific (JSCIF) Buy Recommendation

Berenberg Bank reiterated a Buy on Judges Scientific (OTCPK:JSCIF) on Nov. 26, 2025, with an average one‑year price target of $120.32 (range $100.42–$141.45), implying ~314.89% upside from a $29.00 close; projected annual non‑GAAP EPS is $1.61. Institutional ownership comprises 16 funds (down 2 owners, -11.11% QoQ), total institutional shares fell 4.01% to 338K; major holders include SMALLCAP WORLD FUND INC (172K shares, 2.59%), Fidelity Series Intl Small Cap (50K, 0.75%) and iShares Core MSCI EAFE (35K, 0.53%). The note highlights sizeable analyst upside but modest recent fund de‑risking, relevant for event‑driven or value re‑rating strategies.

Analysis

Market structure: The Berenberg reiteration and a consensus 1-yr target implying +315% (to $120) primarily benefits Judges Scientific (Jscif/JSCIF) holders, research providers and small-cap EAFE allocators (IEFA/SCZ) who can arbitrage re-rating. With institutional ownership only ~338k shares and 16 funds holding positions, free float is thin — current implied forward P/E moves from ~18x (current $29 / EPS $1.61) to ~75x at the target, so a small change in demand can drive large price moves. Liquidity and OTC listing amplify amplitude of moves.

Risk assessment: Tail risks are concentrated: delisting/OTC illiquidity, abrupt single-holder liquidation (SMCWX owns ~172k shares = 2.59%), currency swings if primary operations are GBP, or a one‑off accounting/earnings miss that invalidates the 1.61 EPS. Near term (days): expect noisy moves on headlines/13F changes; short-term (weeks/months): require fresh institutional inflows to sustain rerating; long-term (quarters/years): execution (organic growth or M&A) must justify multiple expansion. Key hidden dependency: ETF/index rebalancing of EAFE small-cap funds can create outsized flows.

Trade implications: Given illiquidity, size positions small and execution-aware. Direct: small long exposure to JSCIF (1–2% NAV), staggered entries and strict size caps; pair trade: long JSCIF vs short SCZ to neutralize regional/small-cap beta until company-specific thesis proves out. Options: LEAP calls are attractive only if open interest/liquidity exists; otherwise use buy-and-covered-call to monetize illiquidity. Catalysts to watch: next quarterly results, 13F filings, any M&A commentary within 90–180 days.

Contrarian angles: The market consensus likely overweights multiple expansion versus operational improvement — the 314% upside is largely multiple-driven and fragile. Historical parallels are microcap reratings that faded absent revenue/cash‑flow proof points; unintended consequence: one large seller or a single negative quarter can erase the rerating. Therefore require concrete evidence (institutional inflows + EPS >1.8 or M&A) before scaling beyond tactical exposure.

Key Decisions for Investors

• Establish a tactical long position in JSCIF equal to 1–1.5% of portfolio NAV, stagger buys between $25–$35; add a second tranche (additional 1%) only if price clears $40 on >2x daily volume and 13F filings show institutional ownership up >5% QoQ. Use an initial stop-loss at -20% absolute or a 90-day time stop if no positive catalysts materialize.
• Implement a relative-value hedge: pair long JSCIF (1% NAV) with a short position in iShares MSCI EAFE Small-Cap ETF (SCZ) equal dollar notional to isolate stock-specific upside; rebalance monthly and unwind the hedge if JSCIF outperformance >40% or if SCZ outperforms by >20% in 60 days.
• If liquid options exist (OI >50, spreads tight), buy 1-year LEAP calls (target strike ~$60) sized to 0.5% NAV. If options are illiquid, buy stock and sell 6–9 month covered calls at ~30% OTM to collect premium and reduce basis.
• Trigger-based scale-up/exit rules: increase total exposure to 3% NAV only if (A) institutional holdings rise >10% QoQ or (B) company reports adjusted EPS ≥1.80 or announces credible M&A within 180 days. Exit or reduce to zero if a top holder (e.g., SMCWX) reduces stake by >50% or price breaches $20 with a 10-day moving-average breakdown.